Awesome results for mTNBC cancer! What makes Leronlimab even more compelling is the lack of side effects for patients. My friends, here we are sitting under $2. Triple digits? I’m a believer.
Check out Trodelvy’s side effects (Gilead’s drug for TNBC that they bought for 21 billion from Immunomedics).
TRODELVY also caused serious side effects, including neutropenia, severe diarrhea, serious infusion-related reactions and allergic reactions that can be life-threatening, and nausea and vomiting in the phase 3 trial.
• Serious adverse reactions occurred in 27% of patients receiving TRODELVY.
• 5% of patients stopped treatment due to side effects
• Side effects leading to a treatment interruption of TRODELVY occurred in 63% of patients
• Doses were reduced for 22% of patients to help manage side effects